In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results